3rd RSC Anglo-Nordic Medicinal Chemistry Symposium
Event
3rd RSC Anglo-Nordic Medicinal Chemistry Symposium
Dates
Tuesday-Friday, 13th-16th June 2023
Place
Hotel Comwell Borupgaard, Snekkersten, Denmark
Downloads and Links
First announcement
Second announcement
Bursary application form – closing date is 3rd May 2023
Venue website (showing location)
Danish travel information website
Twitter hashtag – #ANMC2023
Synopsis
This 2.5 day symposium is the third in the very successful series of biannual meetings started in 2017 containing high quality international speakers from industry and academia on topics of Medicinal Chemistry and related enabling technologies. Organised by the Biological and Medicinal Chemistry Sector of the Royal Society of Chemistry, together with Nordic affiliates, the meeting promises to be an exciting and invigorating gathering packed with fantastic opportunities to disseminate knowledge and expand networks.
The event will include first rate lectures, poster session, trade exhibition, ample networking opportunities, welcome buffet on Tuesday, exceptional location, venue and accommodation.
Who should attend?
Medicinal chemists at all career stages. Scientists with an interest in drug discovery or new technologies that can be applied to the drug discovery process.
Call for Papers
The oral and poster deadline has now passed.
Programme
The scientific programme will feature themed lectures, focusing on medicinal chemistry and related new enabling technologies and disciplines across a range of drug targets and modalities. A distinguishing feature of this symposium is the collegiate style with the delegates living at the premises which encourages an atmosphere of information sharing and learning.
This meeting supports gender balance: Gender diversity quotas to be introduced for Royal Society of Chemistry events | News | Chemistry World
Tuesday 13th June 2023
| 18.00 | Registration opens |
|---|---|
| 18.00 -21.00 | Welcome reception and buffet dinner at Restaurant Borupgaard |
Wednesday 14th June 2023
| 08.30 | Registration opens |
|---|---|
| 09.20 - 09.30 | Opening Remarks |
| Session 1 - New Drug Modalities Session Chair: Annette Graven Sams (Lundbeck) |
|
| 09.30 - 10.30 | Morten Meldal (University of Copenhagen): Title TBC |
| 10.30 - 11.05 | Christiane Kofink (BI): Discovery of the selective and orally bioavailableVHL-recruiting PROTAC ACBI2 showing SMARCA2 degradation in vivo |
| 11.05 - 11.40 | Coffee Break |
| 11.40 - 12.15 | Andreas Ritzen (Monte Rosa): From serendipity to rational drug design: Taking Glue Degraders to new hights |
| 12.15 - 12.50 | Mark Andrews (LEO Pharma): Discovery of an oral, rule of 5 compliant, IL-17A protein-protein interaction modulator for the treatment of psoriasis and other inflammatory diseases |
| 12.50 - 14.00 | Lunch Break |
| 14.00 - 14.30 | Flash poster session Session Chair: Morten Jørgensen (LEO Pharma) |
| 14.30 - 16.00 | Posters and Coffee Break |
| Session 2 - Enabling Science & Technologies (1) Session Chair: Malin Lemurell (AstraZeneca) |
|
| 16.00 - 16.25 | James Murray (Vernalis): PAC-FragmentDEL: PhotoActivated Covalent capture of DNA-Encoded Fragments to identify ligands |
| 16.25 - 16.50 | Nichola Davies (AZ): Structural determinants of orally bioavailable Ro5 and bRo5 drugs |
| 16.50 - 17.15 | Quentin Perron (Iktos): Yes, you should use AI for medicinal chemistry! |
| 19.00 | Dinner |
Thursday 15th June 2023
| 08.30 | Registration opens |
|---|---|
| Session 3 - Target Validation Session Chair: Sharan Bagal (AstraZeneca) |
|
| 09.00 - 10.00 | Mark Bunnage (Vertex): Humanizing Drug Discovery |
| 10.00 - 10.35 | Paul Brennan (University of Oxford): Chemical probes in target discovery |
| 10.35 - 11.10 | Stuart Conway (University Of Oxford): Taking a bump and hole approach to the development of selective degrons |
| 11.10 - 11.45 | Coffee Break |
| Session 4: Enabling Science & Technologies (2) Session Chair: Anne Foley (UCB) |
|
| 11.45 - 12.10 | Thomas Lundbeck (AZ): Application of cellular thermal shift assays |
| 12.10 - 12.35 | Michael Hennig, (leadXpro): Cryo-EM and X-ray structure-based methods in membrane protein drug discovery |
| 12.35 - 13.30 | Lunch Break |
| Session 5: Medicinal Chemistry Case Stories (1) Session Chair: Kevin Dack (LEO Pharma) |
|
| 13.30 - 14.05 | Steve Watson (Sosei-Heptares): The Identification of a GPR52 Agonist clinical candidate; a potential therapy for schizophrenia and related psychiatric disorders (first disclosure) |
| 14.05 - 14.40 | Anne Foley, (UCB): The Discovery and Development of Novel Small Molecule IL17A Inhibitors |
| 14.40 - 15.10 | Coffee Break |
| 15.10 - 15.45 | Ingrid Velter (Janssen Research Development): Discovery of conformationally restricted macrocyclic MCL-1 PPI inhibitors for the treatment of hematological diseases |
| 15.45 - 16.20 | Thomas Ullrich (Novartis): From phenotypic screening to target validation: Discovery of cyclin-dependent kinase-8 (CDK8) inhibitors as inducers of tendon cell differentiation through chemoproteomics |
| 16.20 - 17.20 | Schrodinger Workshop |
| 17.20 - 17.30 | Comfort Break |
| 17.30 - 18.30 | Ray Deshaies (Amgen): Adventures in Chemistry |
| 19.00 | Conference Dinner |
Friday 16th June 2023
| 08.30 | Registration Opens |
|---|---|
| Session 6 - Medicinal Chemistry Case Stories (2) Session Chair: Garrick Smith (Amgen) |
|
| 09.35 - 10.10 | Michael Hahn (Bayer): Discovery of inhaled sGC Activator Mosliciguat (BAY 1237592) for the Treatment of Pulmonary Hypertension |
| 10.10 - 10.45 | Ana Minatti (Amgen): Heterocyclic compounds as delta-5 desaturase inhibitors |
| 10.45 - 11.20 | Coffee Break |
| 11.20 - 11.55 | Jon Winter-Holt (AZ): Optimisation of Mer/Axl kinase inhibitors for immuno-oncology |
| 11.55 - 12.30 | Craig Stivala (Genentech): The development of GDC-2394 - a potent and selective NLRP3 inhibitor |
| 12.30 | Lunch & Depart |
Confirmed Speakers
Discovery of an oral, rule of 5 compliant, il-17a protein-protein interaction modulator for the treatment of psoriasis and other inflammatory diseases
Mark Andrews, LEO, DK
Chemical probes in target discovery
Paul Brennan, University of Oxford, UK
Humanizing Drug Discovery
Mark Bunnage, SVP Vertex, US
Taking a bump and hole approach to the development of selective degrons
Stuart Conway, University of Oxford, UK
Structural determinants of orally bioavailable Ro5 and bRo5 drugs
Nichola Davies, AstraZeneca
Adventures in Chemistry
Ray Deshaies, SVP Amgen, US
The Discovery and Development of Novel Small Molecule IL17A Inhibitors
Anne Foley, UCB, UK
Discovery of inhaled sGC Activator Mosliciguat (BAY 1237592) for the Treatment of Pulmonary Hypertension
Michael Hahn, Bayer, DE
Cryo-EM and X-ray structure-based methods in membrane protein drug discovery
Michael Hennig, leadXpro, CH
Discovery of the selective and orally bioavailable VHL-recruiting PROTAC ACBI2 showing SMARCA2 degradation in vivo
Christiane Kofink, Boehringer Ingelheim, AT
Application of the cellular thermal shift assay in drug discovery
Thomas Lundbäck, AstraZeneca, SE
Title TBC
Morten Meldal, University of Copenhagen, DK
Prof. Morten Meldal is one of the Nobel Laureates in chemistry for 2022!
Heterocyclic compounds as delta-5 desaturase inhibitors
Ana Minatti, Amgen, USA
PAC-FragmentDEL: PhotoActivated Covalent capture of DNA-Encoded Fragments to identify ligands for challenging targets
James Murray, Vernalis, UK
Yes, you should use AI for medicinal chemistry!
Quentin Perron, IKTOS, FR
From Serendipity to Rational Design: Taking Molecular Glue Degraders to New Heights
Andreas Ritzen, Monte Rosa Therapeutics, CH
The development of GDC-2394 – a potent and selective NLRP3 inhibitor
Craig Stivala, Genentech, USA
From phenotypic screening to target validation: Discovery of cyclin-dependent kinase-8 (CDK8) inhibitors as inducers of tendon cell differentiation through chemoproteomics
Thomas Ullrich, Novartis Pharma AG, CH
Discovery of conformationally restricted macrocyclic MCL-1 PPI inhibitors for the treatment of hematological diseases
Ingrid Velter, Janssen Research Development, BE
The Identification of a GPR52 Agonist clinical candidate; a potential therapy for schizophrenia and related psychiatric disorders (first disclosure)
Steve Watson, Sosei Heptares
Optimisation of Mer/Axl kinase inhibitors for immuno-oncology
Jon Winter-Holt, AstraZeneca, UK
Registration
The previous meetings were very popular and fully subscribed to the maximum capacity of 140 attendees.
Registration is now open, click here to register
Early bird registration deadline is 24th March, 2023 23:59(GMT)
Registration deadline: 5th June, 2023, 17:00 (GMT)
Registration Fees
Early bird rate
RSC Member £580.00
Non-Member £665.00
RSC Student** Member* £440.00
Student** Non-member (undergraduate and post-graduate) £485.00
Late registration rate
RSC Member £635.00
Non-Member £720.00
RSC Student** Member* £495.00
Student** Non-member (undergraduate and post-graduate) £540.00
* Member is a paid-up member of the RSC
** Student rates apply to undergraduate and post-graduate students only, but not post-doctoral students.
Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.
Student Bursaries
A limited number of student bursaries are available for this meeting (funded by the RSC-BMCS). The closing date for applications is 3rd May 2023. Please download this bursary application form.
Exhibitor Opportunities
The exhibition package costs £1210 and will include for one full delegate with access to the technical programme.
Each exhibitor stand will comprise a space measuring 1.5 metres wide with electricity and a table measuring 1.5 m wide x 0.75 m deep x 0.72 m high.
Delegate pack inserts may be booked once registration has opened, comprising no more than two pages of A4 fixed together.
Please click here to book your exhibition stand now.
We are grateful to our confirmed exhibitors for their valued support.
Sponsorship
We are grateful to our confirmed sponsors for their valued support.
We are grateful to our supporter: EFMC
Venue
Address: Hotel Comwell Borupgaard, Nørrevej 80, Snekkersten 3070, Denmark
Venue website (showing location)
Travel
These are guide prices which you should verify for yourself, please.
By train: 55 minutes from Copenhagen airport/railway station to Snekkersten. Cost £10-£17
By taxi: 45 minutes from Copenhagen airport/railway station to Snekkersten. Cost £95-£100
By bus and train: 1h 50m from Copenhagen airport/railway station to Snekkersten. Cost £7-£20
Danish travel information website
This is a map with travel modes and charges from Copenhagen station.
Accommodation and Dinners Package
The Accommodation and Dinners Package will comprise:
– three nights’ bed and breakfast accommodation at the conference Hotel Comwell Borupgaard (from Tuesday to Thursday inclusive)
– three-course dinner with drinks on Wednesday
– conference dinner with drinks on Thursday
It will be advisable to book this at the time of registration.
Organising Committee
Sharan Bagal (chair), AstraZeneca, UK
Kevin N Dack, LEO Pharma, DK
Adrian Hall (treasurer), UCB, BE
Malin Lemurell, AstraZeneca, SE
Anette Graven Sams, Lundbeck, DK
Morten Jørgensen (posters), LEO Pharma, DK
Garrick Smith, Amgen Research Copenhagen, DK
Secretariat Contact and Further Information
Hg3 Conferences Ltd
+44 (0)1423 529333
E-mail
